Bayer and Janssen present new data on Xarelto

15 May 2015

New data from an ongoing post-marketing study evaluating the safety of once-daily Xarelto (rivaroxaban) in patients with non-valvular atrial fibrillation (NVAF) were presented at the American Geriatrics Society 2015 Annual Scientific Meeting.

The data show the rates of major bleeding and fatal outcomes in elderly patients treated in routine clinical practice generally are consistent with those reported in Phase 3 clinical trials, which show a correlation between increased age and bleeding.

Xarelto is German pharma major Bayer’s (BAYN: DE) blockbuster anticoagulant, which is co-marketed with Johnson & Johnson (NYSE: JNJ) subsidiary Janssen. Bayer’s sales of Xarelto climbed by 38.4% to 482 million euros ($540 million) in the first quarter of 2015.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK